Catalyst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	596.96	588.99	491.73	398.2	214.2	140.83
Revenue Growth	11.65%	19.78%	23.49%	85.90%	52.10%	18.27%
Cost of Revenue	83.82	87.25	68.85	51.97	34.39	21.88
Gross Profit	513.14	501.74	422.89	346.24	179.81	118.95
Selling, General & Admin	196.16	193.75	177.74	133.71	57.09	49.63
Depreciation & Amortization Expenses	37.86	37.5	37.38	32.57	1.1	-
Research & Development	11.48	12.71	12.65	93.15	19.79	16.94
Total Operating Expenses	245.5	243.96	227.77	259.43	77.97	66.56
Operating Income	267.64	257.78	195.12	86.81	101.84	52.39
Total Non-Operating Income (Expense)	28.82	25.74	21.14	7.7	2.88	0.28
Pretax Income	296.46	283.52	216.26	94.51	104.72	52.67
Provision for Income Taxes	75.14	69.19	52.37	23.1	21.64	13.19
Net Income	221.32	214.33	163.89	71.41	83.08	39.48
Net Income to Common	221.32	214.33	163.89	71.41	83.08	39.48
Net Income Growth	12.15%	30.78%	129.50%	-14.05%	110.42%	-47.34%
Shares Outstanding (Basic)	122	122	118	106	103	103
Shares Outstanding (Diluted)	127	127	125	114	111	108
Shares Change	1.13%	1.85%	9.84%	2.13%	3.32%	1.46%
EPS (Basic)	1.81	1.75	1.38	0.67	0.80	0.38
EPS (Diluted)	1.74	1.68	1.31	0.63	0.75	0.37
EPS Growth	10.83%	28.24%	107.94%	-16.00%	102.70%	-47.89%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	208.13	208.61	239.25	143.37	116.02	59.35
Free Cash Flow Growth	-22.21%	-12.81%	66.88%	23.57%	95.48%	31.82%
Free Cash Flow Per Share	1.64	1.64	1.91	1.26	1.04	0.55
Gross Margin	85.96%	85.19%	86.00%	86.95%	83.94%	84.46%
Operating Margin	44.83%	43.77%	39.68%	21.80%	47.54%	37.20%
Profit Margin	37.08%	36.39%	33.33%	17.93%	38.79%	28.03%
FCF Margin	34.86%	35.42%	48.65%	36.00%	54.16%	42.14%
EBITDA	305.83	295.65	232.9	119.69	103.08	52.58
EBITDA Margin	51.23%	50.20%	47.36%	30.06%	48.12%	37.33%
EBIT	267.64	257.78	195.12	86.81	101.84	52.39
EBIT Margin	44.83%	43.77%	39.68%	21.80%	47.54%	37.20%
Effective Tax Rate	25.34%	24.40%	24.22%	24.44%	20.66%	25.03%

SEC Filings: 10-K · 10-Q